Cost-Effectiveness
ICER Draft Report: High-Cost GLP-1 Obesity Drugs Deemed Cost-Effective—Affordability Still a Concern
ICER; GLP-1; semaglutide; tirzepatide; obesity drugs; cost-effectiveness; health policy; affordability; value-based pricing; cardiovascular benefits
NICE Rejects Alzheimer’s Drug Kisunla Despite UK Regulatory Approval
NICE, Alzheimer’s disease, donanemab, Kisunla, Eli Lilly, MHRA, NHS, cost-effectiveness
ICER Report Suggests Significant Price Reduction for Pfizer’s ATTR-CM Drug Tafamidis
Tafamidis, ATTR-CM, ICER, Pricing, Cost-Effectiveness